AtaiBeckley's DMT film for resistant depression heads to a Q4 readout
Elumina finished dosing at 156 patients, setting up a placebo-controlled MADRS test that will decide whether VLS-01 moves into a broader depression program.
Executive Summary
- AtaiBeckley has finished enrolling and dosing its placebo-controlled trial of a buccal film formulation of DMT in patients who have failed multiple prior antidepressants, with a topline readout expected before year-end.
- The company has tied a positive result to its plan to expand the drug into the much larger major depressive disorder population, making the readout a gate for that broader program rather than an end in itself.
- The trial's completion date has moved twice over the past several months even as enrollment held steady at its original target, a pattern that affects when data arrive more than whether the study is adequately powered.
- No other program in active development for treatment-resistant depression shares this drug's mechanism or delivery route, leaving the result without a direct precedent to benchmark against.
The trial
Elumina (NCT06524830) is an international, multi-center, double-blind, placebo-controlled Phase 2b study testing VLS-01, a buccal transmucosal film formulation of DMT, in adults with treatment-resistant depression. The trial randomized 156 patients 1:1 to VLS-01 or placebo, receiving two double-blind doses two weeks apart, followed by a 12-week placebo-controlled observation period. After that period, all participants are re-randomized to receive one additional open dose at one of two strengths, allowing further characterization of dose response. The primary endpoint is change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score, a clinician-rated 10-item scale for depression severity. NCT06524830+1A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)NCT06524830AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive ...Jul 6, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What's at stake
AtaiBeckley's chief executive, Srinivas Rao, said completing enrollment "keeps us on track for an anticipated topline readout in Q4 2026 and marks the strategic moment to articulate where this program goes next". The company said it intends to advance VLS-01 into a Phase 3 program in major depressive disorder, a broader population than the current trial's treatment-resistant enrollment, "subject to supportive Phase 2 results". It also named generalized anxiety disorder as a potential follow-on indication, citing the drug's two-hour treatment-session design as an advantage for a chronic condition requiring repeat visits. The company separately has BPL-003, a different asset, advancing in Phase 3 for treatment-resistant depression. AtaiBeckleyAtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive ...Jul 6, 2026
Timing history
The trial's primary completion date has moved twice: from December 31, 2025 to March 1, 2026 in February 2026, then to August 1, 2026 in May 2026. Enrollment held flat at its original target of 142 across those changes, which the operational data characterize as a typical pattern rather than a shortfall. The company's public guidance has also shifted, from an H2 2026 topline window disclosed in August 2025 to the current Q4 2026 window disclosed in July 2026. The registered primary completion date of August 1, 2026 falls before the start of that Q4 2026 guidance window, meaning the sponsor's public timeline for reporting data trails the registry's own completion date by roughly two months. NCT06524830+1A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)NCT06524830AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive ...Jul 6, 2026
The competitive field
The nearest active programs in treatment-resistant depression and major depressive disorder work through different mechanisms entirely: esketamine (an NMDA-receptor antagonist) in Phase 3 from Janssen, vortioxetine (a serotonin transporter modulator) in Phase 3 from Takeda, and seltorexant (an orexin-2 receptor antagonist), also from Janssen, are among the mechanistically distinct programs active in the broader indication. None shares VLS-01's serotonergic mechanism or its buccal film delivery route, and no head-to-head competitor for this specific drug and indication combination is active. The field is not sparse in aggregate, with roughly a dozen active programs targeting overlapping depression populations, but it is mechanistically fragmented: no single approach has established itself as the standard beyond ketamine-class and monoamine-based treatments already in use. A MADRS improvement over placebo that holds up through the trial's 12-week placebo-controlled observation period, rather than only at the earliest post-dose assessment, would be the result that supports the company's stated plan to expand into the larger major depressive disorder population.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.